Institute of Tropical Medicine Antwerp, Antwerp, Belgium.
PLoS Negl Trop Dis. 2011 Dec;5(12):e1454. doi: 10.1371/journal.pntd.0001454. Epub 2011 Dec 20.
Trypanosomosis caused by Trypanosoma congolense is a major constraint to animal health in sub-Saharan Africa. Unfortunately, the treatment of the disease is impaired by the spread of drug resistance. Resistance to diminazene aceturate (DA) in T. congolense is linked to a mutation modifying the functioning of a P2-type purine-transporter responsible for the uptake of the drug. Our objective was to verify if the mutation was linked or not to drug pressure.
METHODOLOGY/PRINCIPAL FINDINGS: Thirty-four T. congolense isolates sampled from tsetse or wildlife were screened for the DA-resistance linked mutation using DpnII-PCR-RFLP. The results showed 1 sensitive, 12 resistant and 21 mixed DpnII-PCR-RFLP profiles. This suggests that the mutation is present on at least one allele of each of the 33 isolates. For twelve of the isolates, a standard screening method in mice was used by (i) microscopic examination, (ii) trypanosome-specific 18S-PCR after 2 months of observation and (iii) weekly trypanosome-specific 18S-PCR for 8 weeks. The results showed that all mice remained microscopically trypanosome-positive after treatment with 5 mg/kg DA. With 10 and 20 mg/kg, 8.3% (n = 72) and 0% (n = 72) of the mice became parasitologically positive after treatment. However, in these latter groups the trypanosome-specific 18S-PCR indicated a higher degree of trypanosome-positivity, i.e., with a unique test, 51.4% (n = 72) and 38.9% (n = 72) and with the weekly tests 79.2% (n = 24) and 66.7% (n = 24) for 10 and 20 mg/kg respectively.
CONCLUSION/SIGNIFICANCE: The widespread presence of the DA-resistance linked mutation in T. congolense isolated from wildlife suggests that this mutation is favourable to parasite survival and/or its dissemination in the host population independent from the presence of drug. After treatment with DA, those T. congolense isolates cause persisting low parasitaemias even after complete elimination of the drug and with little impact on the host's health.
由克氏锥虫引起的锥虫病是撒哈拉以南非洲动物健康的主要制约因素。不幸的是,疾病的治疗因耐药性的传播而受到影响。克氏锥虫对二氨基嘧啶(DA)的耐药性与一种突变有关,该突变改变了一种负责摄取药物的 P2 型嘌呤转运体的功能。我们的目的是验证该突变是否与药物压力有关。
方法/主要发现:使用 DpnII-PCR-RFLP 对从采采蝇或野生动物中采集的 34 株克氏锥虫分离株进行了与 DA 耐药相关的突变筛选。结果显示,1 株敏感,12 株耐药,21 株混合 DpnII-PCR-RFLP 图谱。这表明该突变至少存在于 33 个分离株中的每一个的一个等位基因上。对于 12 个分离株,通过(i)显微镜检查,(ii)2 个月观察后的锥虫特异性 18S-PCR 和(iii)8 周每周锥虫特异性 18S-PCR,使用了一种在小鼠中的标准筛选方法。结果显示,在用 5mg/kg DA 治疗后,所有小鼠在显微镜下仍呈锥虫阳性。用 10 和 20mg/kg 治疗时,8.3%(n=72)和 0%(n=72)的小鼠在治疗后寄生虫学上呈阳性。然而,在后两组中,锥虫特异性 18S-PCR 表明锥虫阳性程度更高,即使用单一测试时,51.4%(n=72)和 38.9%(n=72),每周测试时分别为 79.2%(n=24)和 66.7%(n=24)。
结论/意义:从野生动物中分离出的克氏锥虫广泛存在与 DA 耐药相关的突变表明,该突变有利于寄生虫的生存和/或其在宿主群体中的传播,而与药物的存在无关。用 DA 治疗后,即使完全消除了药物,那些克氏锥虫分离株仍会导致持续的低寄生虫血症,而且对宿主的健康几乎没有影响。